Description: Develop a better understanding of specialty drug trends and their increasing healthcare costs for more than the past decade by attending this webcast. With the introduction of price competition, you will see changes in the market for biosimilar products and patent-protected drugs. For example, the drug Humira will be gaining 10 biosimilar competitors in 2023. Alone, Humira can represent over 20% of total pharmacy spend for health plans. Join us and discover how price competition is a turning point for the pharmaceutical industry and will define its direction for the next decade.

Description: Explore historical trends in enrollment, carrier participation, and competition over the first 10 years of the individual marketplace as a basis to frame what the future could hold for the next 10 years. Draw parallels to other lines of business (e.g., Medicare Advantage, employer group) as we look at how the market may evolve and the capabilities required to succeed. This session would be valuable for anyone interested in consumer purchasing behavior, quality and risk adjustment, employer benefits, provider dynamics, and the individual market more broadly. By attending this this session, you will be able to articulate the impact of recent legislation and regulatory actions on the Individual market, including subsidies, employer funding vehicles (e.g., ICHRA), distribution channels, and product requirements.

Description: Management service organizations (MSOs) in value-based care have expanded into far more locations in the health care ecosystem; some demonstrate value to both buyers and providers. Explore the role of these players in the health care ecosystem, their future outlook, and how actuaries can help them perform.

Description: Prepare for an interactive session around how members choose a Medicare Advantage Plan, and how actuaries can help be part of the discussion! You will participate in a decision-making activity to set the stage for understanding member selection. Then, dive into an actuarial analysis of the 2023 Medicare Advantage competitive landscape, with an emphasis on what benefits drive membership decisions. This presentation will evaluate plan components prevalent amongst the strongest plan offerings in the market, including supplemental benefit prevalence, member cost sharing, and the underlying benefit value. You will better understand which benefits drive the most significant membership changes, as well as how to think about what the most impactful benefit changes will be for 2024.

Description: There exists profound health and access disparities among people from different demographics and socioeconomic backgrounds. Health equity is now a central policy directive for the U.S. government and CMS. Speakers representing policy, health care delivery and actuarial spaces will help you discover what health equity policy directions may look like, the challenges health care providers are facing and how actuaries can contribute to the effort in bridging the health equity divides.

Description: The Society of Actuaries will host two great events for the health actuarial community, bringing together the industry’s leading actuaries, analysts and professionals to network and discuss impacts of the latest marketplace factors and trends.

Description: Investigate Deloitte's methodology to quantify the cost of health inequities attributable to racial bias, gender/sex bias and socioeconomic bias. We will illustrate the methodology by calculating total potential cost savings across different disease states and discuss both the role that actuaries play in addressing health inequity and the steps that organizations can take to activate health equity.

Description: How do we take a Minimum Viable Products (MVP) approach to launch new insurance products? Join this moderated discussion and focus on three key development aspects: Distribution, Systems, and the design and pricing of the Insurance product itself. Come discuss reasons to choose an MVP approach and how it solves many of the product launch challenges.

Description: This is Part 2 of 2 on changes affecting Medigap insurers. It focuses on marketing and regulatory differences between Medigap and Medicare Advantage that affect the competitiveness of Medigap plans.

Description: Health insurance company assets and liabilities have evolved since the Patient Protection and Affordable Care Act (ACA) was signed into law in March 2010. The ACA fundamentally rearranged how commercial health insurance is funded by integrating federal premium subsidies and pass-throughs together with a marketplace interwoven with transfer payments among stakeholders. The impacts of these programs can be seen in specific accounting items on the balance sheets of health insurance companies over the past 10 years. Their emergence follows three primary trends: (1) balance sheet items tend to be larger and take longer to settle, (2) there are more interactions among items, and (3) the final settlement amounts are more uncertain.